Duranil

Quick links to important sections

Duranil

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Duranil

What is Duranil? Defining the Hexetidine Anti-infective

Property Description
Active ingredient Hexetidine (C₂₁H₄₅N₃)
Form Topical Solution (Mouthwash/Gargle, Spray)
Pharmacological Class Antiinfective and Antiseptic (A01AB12)
Common Use Local oral and pharyngeal hygiene and discomfort relief
Origin Synthetic (Diazinane derivative)

Duranil is a synthetic medicinal product formulated specifically for local oral treatment, containing Hexetidine as its sole active pharmaceutical ingredient. Hexetidine is officially indexed with the Anatomical Therapeutic Chemical (ATC) code A01AB12, confirming its established classification for use in the mouth. This classification supports its recognized role as a nonantibiotic antimicrobial agent intended for localized pathogen management.

Hexetidine is chemically a diazinane derivative (C₂₁H₄₅N₃), a compound whose structure is supported by pharmacological studies. This design distinguishes it from systemically administered antibiotics by ensuring its action is localized to the surface tissues. Duranil is consistently formulated as a topical solution for local administration, which maximizes contact with mucosal surfaces. This specific delivery method is intended for its antiseptic properties targeting infections of the mouth and throat. Its primary purpose is to promote oral and pharyngeal hygiene by providing effective broad-spectrum germ-killing action (bactericidal and fungicidal) and offering immediate local numbing sensation to relieve associated discomfort.

What side effects are possible with Duranil?

Possible Side Effects and Safety Information

The safety profile of Duranil (Hexetidine) is defined by officially documented adverse reactions, which are primarily localized and classified according to regulatory standards. The medicine's risk profile is structured around potential local effects and rare, but serious, hypersensitivity responses, as detailed in governmental prescribing information.

Frequency-Classified Adverse Reactions

Many documented effects are classified as Not Known (frequency cannot be estimated from available post-marketing data). These include taste disturbance (dysgeusia/ageusia), local irritation at the application site, dry mouth, and tongue or tooth discoloration. Localized effects like transient numbness (Very Rare) have also been reported.

System-Organ Classes and Serious Events

Adverse reactions are formally grouped within specific System-Organ Classes (SOCs), most commonly involving Gastrointestinal Disorders (local reactions) and Nervous System Disorders (taste changes). The most significant, though infrequent, safety concern involves Immune System Disorders.

Classification Examples of Reactions
Serious Adverse Reactions Anaphylactic reaction, Angioedema (swelling related to severe allergic response)

Safety Constraints and Restrictions

Duranil is associated with specific regulatory restrictions. It is contraindicated (must not be used) in individuals with known hypersensitivity to the active ingredient or excipients, or in patients presenting with erosive-desquamative changes in the oral mucosa. Furthermore, its use is contraindicated in the pediatric population under 3 years of age.

This official safety documentation establishes the need to observe these specific limitations and be aware of the potential for localized effects and systemic hypersensitivity.

Overdose and Emergency Response

Overdose and When to Seek Help

The officially documented profile for overdose with Duranil topical solution is primarily linked to the product’s ethanol excipient, not the active ingredient Hexetidine. Regulatory bodies confirm that the Hexetidine component is considered non-toxic at formulation strength, meaning its effects in overdose do not extend beyond those seen during normal use. This classification strictly governs all required emergency actions and supportive measures.

Overdose Manifestations and Risk

Element Official Regulatory Statement
Documented Manifestations Clinical signs are consistent with acute alcoholic intoxication resulting from the ingestion of the ethanol content.
Exposure-Related Factors Overdose risk is associated only with the massive accidental ingestion of the entire bottle contents, not routine use.
Affected Populations The potential for serious outcomes is specifically highlighted for the small child, who is most susceptible to the effects of the ethanol excipient. Warnings also exist for high-risk groups such as patients with liver disease or epilepsy.

Emergency Action and Management

Regulatory authorities mandate that a doctor must be consulted immediately in the event of accidental ingestion of the contents of a bottle by a child. This immediate action is the required trigger for urgent medical attention. Treatment is defined as symptomatic and focuses on managing the clinical presentation of alcoholic intoxication. Gastric lavage should be considered if the ingestion occurred within the preceding two hours, as a regulator-documented procedural step. The overall regulatory structure dictates that the management protocol must address the effects of the excipient.

Therapeutic Uses of Duranil

What Duranil Treats: Main Uses and Benefits

Duranil is broadly applicable in situations involving certain distressing symptoms across a range of conditions. The medicine's therapeutic role is primarily defined by its domain of use and the specific symptoms it helps address.

It is commonly used to help address groups of symptoms, including those related to physical discomfort, symptoms that interfere with daily functioning, and symptoms associated with acute or episodic changes. It is applied across domains where additional symptomatic support is needed, particularly in conditions involving episodic or fluctuating manifestations. In these situations, Duranil provides support that helps ease the overall symptom burden.

Quick Fact: Assistance for Episodic Distress

The medicine assists with managing symptom clusters that may become intense or disruptive, supporting the patient's sense of stability when symptoms are more noticeable.


Easing Symptomatic Discomfort

The medicine is considered relevant in contexts marked by increased discomfort or tension, and it assists with managing symptom clusters that may become intense or disruptive. It provides support that helps ease the overall symptom burden, and may support day-to-day comfort during symptomatic periods.


Supporting Functional Stability

Duranil is applied across domains where additional symptomatic support is needed, particularly when groups of symptoms appear suddenly or fluctuate, creating noticeable functional strain. It supports patients during periods of functional strain, and offers symptomatic relief that helps patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Who Can and Cannot Use Duranil? (Hexetidine)

Official regulatory documents define specific populations who are permitted, restricted, or prohibited from using Duranil topical solution. Eligibility rules are primarily based on age, physiological status, and the presence of certain local conditions.

Contraindications and Non-Eligibility

Use of Duranil is strictly contraindicated and must be avoided by the following patient groups:

  • Individuals with a known hypersensitivity or allergy to Hexetidine or any other components in the formulation.
  • Patients diagnosed with atrophic pharyngitis.
  • Patients presenting with desquamative-erosive lesions of the oral mucosa.
  • Children under 6 years of age (use is not recommended or established).

Age and Physiological Restrictions

Population Group Eligibility Status Restriction Summary
Adults and Adolescents (12+ years) Permitted Standard labeled use.
Children (6 to 12 years) Restricted Use is permitted but requires medical supervision.
Pregnancy/Lactation Not Recommended Use is not recommended, particularly during the first trimester of pregnancy and while breastfeeding.

Continuous use of Duranil is subject to a limitation and should generally not exceed 10 days, as specified in regulatory labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Duranil (Hexetidine) interaction patterns is governed by its local, topical administration and negligible systemic absorption, which is consistent with the product's official status as a non-systemic antiinfective.

Official Interaction Status

Interaction Type Regulatory Finding (Active Ingredient)
Drug-Drug Interactions No interactions are known for the active substance Hexetidine with other medicinal products.
Pharmacokinetic Profile No documented metabolic (CYP) or transporter-mediated interactions are known.

The official Summary of Product Characteristics (SmPC) establishes that no systemic interactions are known for Hexetidine, confirming the absence of documented effects on the clearance or exposure (AUC/Cmax) of co-administered medicines. This classification means there are no formal timing-based administration rules or restrictions on co-administration specifically due to the active ingredient.

Product Formulation Caution

The most significant interaction caution documented in official labeling relates not to Hexetidine, but to an excipient in the topical solution. Because the formulation contains Ethanol (alcohol), a caution is mandated that swallowing the medicinal product may potentially alter the effects of other concurrent medications. This results in a specific regulatory note advising patients with alcohol addiction to consult a healthcare professional regarding the product’s ethanol content prior to use.

Mechanism of Action

How Duranil Works

The mechanism of action for Hexetidine (Duranil) is characterized by a dual, strictly localized effect confined to the oral and pharyngeal surface, defined by two parallel mechanistic domains: microbial cell disruption and peripheral sensory nerve stabilization.


Disruption of Microbial Cell Structure and Metabolism

This domain describes the mechanism of action involving pathogen cell structure and metabolism. The molecule, being cationic, quickly binds to the negatively charged microbial cell membrane of bacteria and fungi, causing immediate physico-chemical disruption and leakage of essential intracellular components. Concurrently, Hexetidine inhibits key oxidative enzymes required for microbial growth. This dual molecular cascade results in the cellular lysis and death of the pathogen.


Peripheral Sensory Nerve Stabilization

This domain covers the parallel mechanism which involves the modulation of sensory nerve signaling. Hexetidine acts as a membrane-stabilizing agent on the peripheral sensory nerve endings in the mucosa. By blocking the ion channels necessary for impulse generation, it inhibits the transmission of the peripheral afferent impulse. This mechanistic consequence establishes a state of peripheral sensory desensitization at the point of application.


Mechanism Scope and Localized Action

The mechanism of action is exclusively peripheral and dependent on maximal surface retention, as the molecule is minimally absorbed systemically. This anatomical restriction means that the physiological consequences of cell death and nerve blockade are isolated to the site of application. The functional consequence is limited by the molecule's finite retention time on the mucosal surface.

Dosage and Administration Information

Duranil is applied exclusively by the oromucosal route as a topical solution for local action, consistent with its classification as an antiseptic agent intended for surface application to the mouth and throat linings. The solution is formulated at a 0.1% concentration and must be used undiluted for each application.

The standard application protocol involves measuring 10 mL to 20 mL of the solution. This volume is then used to rinse the mouth or gargle the throat for a duration of approximately 30 seconds. Following the application, the solution must be completely expelled and is strictly not for swallowing, which is a key procedural instruction to limit systemic exposure.

Usage is governed by a defined schedule of two to three times daily. The product is intended only for short-term courses, reflecting its role in acute usage patterns. Usage guidelines specify that use should generally not exceed 7 to 10 days without consulting a health professional.

For specific populations, use is subject to age restrictions: the medicine is not recommended for children under 6 years of age. For children between 6 and 12 years, administration of Duranil must be conducted under adult supervision. These rules delineate the precise conditions for using the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies for Duranil


Evidence for Use in Oral Hygiene and Plaque Control

Research exploring Duranil, which contains Hexetidine, primarily involves short-term Randomized Controlled Trials (RCTs) and Systematic Reviews focused on oral hygiene management. These studies were generally applied in contexts involving healthy adults or those with mild gingivitis. The main goal was to monitor changes in standardized scores related to supragingival plaque accumulation and indices related to gingival inflammation.

Findings describe patterns observed in the studies, where research monitored changes measured during the study period. Some research also explored comparisons between Duranil and placebo or other common oral hygiene agents. However, follow-up durations were limited, and there is limited information for long-term outcomes regarding sustained plaque control.


Evidence for Managing Acute Oral and Throat Discomfort

The evidence base includes short-duration RCTs and Comparative Studies focusing on acute phases of local conditions, such as pharyngitis and oral inflammation. This research examined outcomes related to physical discomfort and inflammatory states. Studies primarily included outpatients with acute symptoms of a sore throat or specific oral lesions.

Research monitored how symptoms evolved in the observed populations, with a focus on assessing patient-reported outcomes describing perceived discomfort, pain, and local inflammation scores. The certainty remains low to moderate for this indication due to several research limitations, including very limited follow-up durations (often only a few days).


Uncertainties, Research Gaps, and Study Limitations

Research has explored Duranil's broad-spectrum germ-killing action through clinical trials and laboratory-based (in-vitro) assays against bacteria, fungi, and certain viruses. Findings show patterns related to a rapid reduction in the counts of certain oral microorganisms. However, the clinical relevance of these in-vitro findings to managing infections is not fully established.

Evidence quality varies across studies, particularly for acute throat inflammation where sample sizes were modest. Research has not fully established the long-term effects of repeated, daily use. Furthermore, data for certain groups remain insufficient, including for younger children and patients with complex comorbid conditions.

Key Studies & References The effect of hexetidine mouthwash on the prevention of plaque and gingival inflammation: a systematic review

Frequently Asked Questions (FAQ)

Common questions about Duranil (FAQ)

Q: How quickly does Duranil start working after you take it?

According to official information, the active ingredient in Duranil binds rapidly to the lining of the mouth and throat. The quick binding action is consistent with the expected onset of the immediate local numbing sensation described in official documents.

Q: Can older adults (over 65) use Duranil safely?

Official product information does not list any specific safety constraints or dose adjustments for adults over 65 years old. Official documents state that the general adult use guidelines apply.

Q: Does Duranil lose effectiveness over time if stored improperly?

Regulatory guidelines specify strict storage requirements to maintain the product's quality, stability, and intended effectiveness over time. If the solution is exposed to freezing, excessive heat, or moisture, its original properties may be compromised.

Q: How long does Duranil stay in your system after the last dose?

Information regarding the exact time the drug remains in the body is limited because Duranil is minimally absorbed into the bloodstream. Its action is strictly local to the mouth and throat lining, and the solution is intended to be expelled after each use.

Q: Are there different strengths or dosages of Duranil available?

The topical solution is typically formulated at a single, standard concentration (0.1%) for its designated use as a mouthwash or gargle. Any potential variation in product concentration or form would be detailed in the official product characteristics.

Q: Does the drug label mention any serious risks associated with long-term Duranil use?

Official regulatory guidance emphasizes that this medicine is intended for short-term courses only, generally not to exceed 7 to 10 days. Research and official documentation do not support its routine or continuous long-term use.

Q: Has Duranil been studied in pregnant or breastfeeding populations?

Official product information states that use is not recommended during the first three months of pregnancy or while breastfeeding. This is often because there is insufficient clinical data available to fully establish the product's safety for these populations.

Q: Does Duranil cause allergic reactions, and what are the signs?

While rare, serious allergic reactions, classified as Anaphylaxis or Angioedema, are listed in official safety documentation. Official documents describe the signs of these severe responses as including sudden swelling of the face, throat, or tongue, a widespread rash, or difficulties breathing.

Q: Why do some people report feeling no difference after starting Duranil?

Official summaries of research evidence for acute discomfort indicate that studies had low to moderate certainty and limited follow-up periods. This inherent variation in the scientific data may correlate with different patient experiences and reported outcomes.

Q: Does Duranil contain lactose or other common allergens?

The official product label provides a full list of all inactive ingredients, or excipients. A known caution noted in the product information is related to the presence of Ethanol (alcohol). The full list of excipients must be reviewed for the presence of any other specific allergens.

Q: What is the half-life of Duranil?

The specific pharmacokinetic data, such as the half-life, is not routinely provided in official regulatory documents. This is because Duranil is a strictly topical medicine designed for localized action with only negligible absorption into the body.

Q: Are there any common foods or drinks that should be avoided while taking Duranil?

Since Duranil is a topical solution that must be expelled, no specific interactions with common foods or non-alcoholic beverages are known or documented in the official labeling. The only formulation caution is related to the alcohol (Ethanol) content if the solution is swallowed.

Q: Why are people saying Duranil made them feel dizzy?

Dizziness is not listed as a known or reported adverse reaction in the official regulatory product information for Duranil.

Q: Is the tiredness mentioned as a side effect of Duranil common or rare?

Tiredness or fatigue are not listed as known or reported adverse reactions in the official regulatory documentation for Duranil.

Q: Does Duranil affect sleep patterns?

Disturbances to sleep patterns are not listed as a known or reported adverse reaction in the official regulatory documentation for Duranil.

Q: Is it safe to drive or operate machinery while taking Duranil?

Official labeling states that Duranil has no or negligible influence on the ability to drive or operate machinery. This status is based on its localized use and minimal systemic absorption into the body.

Q: Is Duranil known to cause weight gain or weight loss?

Weight gain or weight loss are not listed as known or reported adverse reactions in the official regulatory documentation for Duranil.

Q: Can Duranil affect the results of blood tests?

Because Duranil is intended for topical use and has minimal systemic absorption, official regulatory documents do not suggest that the medicine affects the results of routine blood tests.

Q: Is it normal to have mild stomach upset when first starting Duranil?

Official product information sometimes lists localized gastrointestinal effects, such as dry mouth or a change in taste. However, general systemic 'stomach upset' is not typically listed as a common documented side effect.

Q: Is there a generic version of Duranil available?

The active ingredient in Duranil, Hexetidine, is a well-known antiseptic ingredient that is widely available under various brand names and is commonly sold over-the-counter (OTC).

Q: Can Duranil interact negatively with herbal supplements or vitamins?

Regulatory documents confirm that there are no known interactions between the active substance, Hexetidine, and other medicinal products. This statement extends to common herbal supplements and vitamins.

Q: Are there any special warnings or black box warnings for Duranil?

Official labeling does not contain a U.S. FDA Black Box Warning or an equivalent special warning from European regulatory bodies. Warnings primarily emphasize the risk of hypersensitivity and the strict instruction not to swallow the solution.

Q: Can Duranil affect mood or cause emotional changes?

Mood or emotional changes are not listed as known or reported adverse reactions in the official regulatory documentation for Duranil.

Q: Is Duranil considered a controlled substance by the government?

Duranil (Hexetidine) is classified as a local antiseptic agent and is not listed as a controlled substance by government regulatory agencies in any jurisdiction. It is generally available without a prescription.

Q: Is Duranil safe for people with liver or kidney problems?

Because the drug is for localized use and is only minimally absorbed into the body, official labeling typically does not include specific warnings or requirements for dose adjustments related to existing liver or kidney impairment.

Q: Is the purpose of Duranil to cure a condition or just manage symptoms?

The official purpose of Duranil is defined as a local anti-infective and antiseptic, supporting local oral treatment and the temporary relief of discomfort. This function is typically associated with managing symptoms and maintaining local hygiene rather than providing a systemic cure.

Q: Are there any known withdrawal effects when stopping Duranil?

Withdrawal effects or dependence symptoms upon stopping the medicine are not listed as known or reported reactions in the official product documentation.

How should Duranil be stored and disposed of?

How to Store and Dispose of Duranil (Hexetidine Topical Solution)

Storage and disposal must adhere to official regulatory guidance to maintain product quality and safety.

Storage Conditions

Category Regulatory Requirement
Temperature Store at controlled room temperature, generally 20 C to 25 C (68 F to 77 F).
Protection Must be protected from freezing, excessive heat, and moisture.
Container Keep in the original container and ensure it is tightly closed when not in use.
Child Safety Keep out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Unused or expired Duranil should be discarded via a drug take-back program as the primary method. If a program is unavailable, mix the solution with an undesirable substance (e.g., dirt) and seal the mixture in a container before placing it in household trash. Do not flush the product down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Duranil found in:

A-Z Index: